Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2

Status

Terminated 3Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 5Lymphoid 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 45Recurrence 6Leukemia, Myeloid, Acute 5Waldenstrom Macroglobulinemia 2Smoldering Multiple Myeloma 2Plasmacytoma 2Lymphoma, Large B-Cell, Diffuse 2Immunoglobulin Light-chain Amyloidosis 2Carcinoma, Non-Small-Cell Lung 2Various Advanced Cancer 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Microsatellite Unstable Colorectal Cancer 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hypergammaglobulinemia 1Hodgkin Disease 1Amyloidosis 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Recurrence × daratumumab × Clear all
NCT04824794 2026-05-19

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Genmab

Phase 1/2 Terminated
130 enrolled 40 charts
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Celgene

Phase 1/2 Active not recruiting
466 enrolled 57 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT03450057 2024-03-29

DARE

Hellenic Society of Hematology

Phase 2 Completed
38 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT03679624 2023-10-23

Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia

Weill Medical College of Cornell University

Phase 2 Terminated
1 enrolled 8 charts
Lymphoid

Hypergammaglobulinemia, Waldenstrom Macroglobulinemia, Recurrence

NCT02807454 2023-02-21

FUSIONMM-003

Celgene

Phase 2 Terminated
37 enrolled 21 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT03000452 2018-10-16

FUSION-MM-005

Celgene

Phase 2 Completed
18 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡